• Platform & Pipeline
    • Opportunity
    • CAR T-Cell Therapy
    • Pipeline
    • Clinical Trials and Expanded Access
  • Patients
    • Experience
    • Stiff Person Syndrome
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Lupus Nephritis
    • Systemic Sclerosis
  • Inside Kyverna
    • Leadership
    • Mission & Values
  • Education & Events
    • Events
    • Publications
    • Videos
  • Investors
  • News
  • Careers
  • Contact

Pipeline

A focused pipeline of B-cell targeting therapies to address autoimmune diseases.

Pipeline chart

Learn more about our disease targets

Stiff Person Syndrome
Myasthenia Gravis
Multiple Sclerosis
Lupus Nephritis
Systemic Sclerosis

Links

  • Home
  • Platform & Pipeline
  • Patients
  • Inside Kyverna
  • Education & Events
  • Investors
  • Careers
  • Contact

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

  • Privacy Policy (US)
  • Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress